Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Verrica Pharmaceuticals Inc. has received an average analyst rating of "Hold" from five coverage groups, with four analysts recommending hold and one analyst giving a buy recommendation.
• As of now, the company's stock price is $5.57, which reflects a decline of 1.2%, and its 12-month target price from analysts averages $80.00.
• Following its last earnings report, Verrica Pharmaceuticals posted a loss of ($1.00) EPS, outperforming consensus estimates and achieving revenues of $3.44 million for the quarter.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been assigned a consensus rating of "Hold" from the five research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $80.00.

Several analysts have issued reports on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caligan Partners LP acquired a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth approximately $5,201,000. Boothbay Fund Management LLC purchased a new stake in Verrica Pharmaceuticals in the 4th quarter worth approximately $1,811,000. Sovran Advisors LLC boosted its stake in shares of Verrica Pharmaceuticals by 91.3% during the 2nd quarter. Sovran Advisors LLC now owns 750,391 shares of the company's stock valued at $398,000 after buying an additional 358,228 shares during the period. Heights Capital Management Inc. acquired a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth $246,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the second quarter worth $99,000. Institutional investors and hedge funds own 42.45% of the company's stock.

Verrica Pharmaceuticals Price Performance

VRCA stock traded up $0.26 during midday trading on Tuesday, reaching $6.37. 9,094 shares of the company's stock traded hands, compared to its average volume of 41,815. Verrica Pharmaceuticals has a fifty-two week low of $3.82 and a fifty-two week high of $58.20. The business has a 50-day moving average price of $6.56 and a two-hundred day moving average price of $6.07. The company has a market capitalization of $58.92 million, a P/E ratio of -0.53 and a beta of 1.92.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.40) by $0.40. The company had revenue of $3.44 million for the quarter, compared to analyst estimates of $2.53 million. As a group, research analysts forecast that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.